Pfizer and BioNTech have announced the commencement of a clinical trial that will evaluate the safety, tolerability and immunogenicity of a candidate mRNA vaccine based on the Omicron variant.
Healthy adults aged 18 to 55 will participate in the study. Researchers will also compare the effects of administering the new vaccine with the different administration regimens of the current one.
Furthermore, some participants in the Phase 3 booster dose trial of the currently available COVID-19 vaccine...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
